There are 2137 resources available
681P - Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)
Presenter: Ravi Madan
Session: E-Poster Display
Resources:
Abstract
682P - Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer
Presenter: Mark Tuthill
Session: E-Poster Display
Resources:
Abstract
683P - Correlation between castration resistant prostate cancer (CRPC) free survival (CRPC-FS) and metastasis free survival (MFS) in men initiating androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after radical prostatectomy (RP): Results from the SEARCH database
Presenter: Stephen Freedland
Session: E-Poster Display
Resources:
Abstract
684P - The real effects of prostate cancer chemotherapy: Results of the EUPROMs prostate patient-driven quality of life study
Presenter: André Deschamps
Session: E-Poster Display
Resources:
Abstract
685P - A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response
Presenter: Maha Hussain
Session: E-Poster Display
Resources:
Abstract
686P - Macrophage composition as a prognostic indicator of time to progression and radiotherapy response in prostate adenocarcinoma
Presenter: Neil Jairath
Session: E-Poster Display
Resources:
Abstract
687TiP - ARC-6: A phase Ib/II, open-label, randomized platform study evaluating the efficacy and safety of AB928-based treatment combinations in patients with metastatic castrate resistant prostate cancer
Presenter: Sumit Subudhi
Session: E-Poster Display
Resources:
Abstract
688TiP - Genetic information to inform treatment and screening (GIFTS) study for prostate cancer: Characterizing germline DNA alterations in men with metastatic prostate cancer and their first-degree male relatives
Presenter: Risa Wong
Session: E-Poster Display
Resources:
Abstract
689TiP - NRG Oncology’s GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)
Presenter: Zachary Zumsteg
Session: E-Poster Display
Resources:
Abstract
690TiP - A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)
Presenter: Charles Drake
Session: E-Poster Display
Resources:
Abstract